Instil Bio(US:TIL)2025-11-13 12:05Financial Performance - As of September 30, 2025, Instil Bio had cash and cash equivalents of $5.8 million, down from $8.8 million as of December 31, 2024, representing a decrease of 34%[3] - The net loss per share for Q3 2025 was $2.01, compared to $3.54 for Q3 2024, indicating an improvement of 43%[6] - Non-GAAP net loss per share for Q3 2025 was $1.75, compared to $2.55 for Q3 2024, showing a decrease of 31%[7] - The company reported a net loss of $13.6 million for Q3 2025, compared to a net loss of $23.0 million for Q3 2024, a reduction of 41%[16] Expenses - Research and development expenses increased to $9.1 million for Q3 2025, compared to $0.6 million in Q3 2024, reflecting a growth of 1417%[4] - General and administrative expenses decreased to $5.9 million for Q3 2025, down from $10.7 million in Q3 2024, a reduction of 45%[5] - Total operating expenses for the nine months ended September 30, 2025, were $69.0 million, compared to $61.7 million for the same period in 2024, an increase of 12%[16] Assets and Cash Flow - Instil Bio's total assets as of September 30, 2025, were $211.8 million, down from $263.6 million as of December 31, 2024, a decline of 20%[14] - Instil Bio expects its current cash resources to fund its operating plan beyond 2026[3] Clinical Trials - The first patient was dosed in a Phase 1 clinical trial evaluating AXN-2510 as monotherapy in patients with advanced solid tumors[2]